Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mouse study could aid vaccine designers

28.05.2004


Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s "killer" T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.



The findings are published in this week’s Science. "If we are correct, what we’ve found will put rational vaccine design on a firmer footing," says Jonathan Yewdell, M.D., Ph.D., who led the NIAID team.

T cells belong to the cellular arm of the immune system’s two-pronged defense mechanism against foreign invaders--the other arm features blood-borne antibodies. Historically, vaccines aimed to stimulate antibody production in a bid to prevent specific diseases. More recently, scientists have begun to manipulate T cells to create vaccines effective against pathogens that antibodies alone cannot control. Such T-cell-inducing vaccines are being tested against infectious diseases such as HIV/AIDS and hepatitis and are being studied as treatments for certain cancers.


Once alerted to the presence of infected cells, resting T cells are "awakened" and begin to multiply rapidly. Then they zero in on and destroy infected cells while sparing uninfected ones. Rousing slumbering T cells is the job of dendritic cells, the sentinels of the immune system. Dendritic cells activate the T cells by displaying peptides--small pieces of virus or other foreign protein--on their surfaces. In a process called direct priming, dendritic cells generate these peptides by themselves after being infected by a virus. Alternatively, dendritic cells may first interact with other body cells that have been infected by a virus and then activate the T cells. This indirect route is called cross-priming.

Vaccines may exploit either route to T-cell priming, but scientists have not known enough about the mechanisms behind cross-priming to exploit this route in vaccine design.

Test tube experiments suggested that molecular "chaperones" accompany peptides from infected cells to dendritic cells, and a number of experimental vaccines have been designed on this premise. But few studies have been done to determine if chaperoned peptides play any role in animal systems, notes Dr. Yewdell.

If the chaperoned peptide theory is correct, infected cells that make the most peptides should most strongly stimulate cross-priming. Conversely, fewer peptides should mean less cross-priming. To test this prediction, Dr. Yewdell and his colleagues created virus-infected cells that were genetically or chemically prevented from producing peptides and injected those cells into mice. They found the opposite of what they expected: cross-priming correlated directly with levels of whole proteins, rather than levels of peptides, expressed by the virus-infected cells.

This new information could aid vaccine design, says Dr. Yewdell. "Our experiments indicate that two distinct pathways exist to prime T cells," he says. If the rules for T-cell priming suggested by these experiments are correct, vaccines meant to interact with dendritic cells should be designed to generate large amounts of peptides, while vaccines that target other kinds of cells should be designed to generate whole proteins that will go on to be processed in the dendritic cells during T-cell cross-priming.

Prompting a strong and specific T-cell reaction may be the key to vaccines that are effective against certain infectious diseases, including HIV/AIDS and malaria, notes Dr. Yewdell. It is also possible that a therapeutic vaccine might be developed to boost the T cell activity of people who have chronic liver infections caused by hepatitis B or C viruses.


NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.

Reference: CC Norbury et al. CD8+ cell cross-priming via transfer of proteasome substrates. Science 304:1318-21 (2004).

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

Anne A. Oplinger | EurekAlert!
Further information:
http://www.niaid.nih.gov

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>